EC-8042在ERG阳性前列腺癌中通过转录重编程抑制肿瘤增殖性干细胞样细胞
本文在细胞培养和ERG/PTEN转基因/敲除小鼠模型中测试EC-8042(可阻断SP1)对ERG阳性前列腺癌的活性。EC-8042阻断ERG调控基因转录,逆转VCaP细胞的侵袭和转移表型,抑制肿瘤球中干细胞样肿瘤细胞扩增;在ERG/PTEN小鼠中全身治疗抑制ERG调控基因转录、肿瘤进展和肿瘤增殖性干细胞样肿瘤细胞。数据支持在精准医学方法中对ERG阳性前列腺癌进行EC-8042的临床测试。
要点
- EC-8042阻断ERG调控基因转录并逆转VCaP细胞的侵袭和转移表型。
- EC-8042抑制VCaP细胞和小鼠来源肿瘤球中干细胞样肿瘤细胞的扩增。
- ERG/PTEN小鼠全身EC-8042治疗抑制ERG调控基因转录、肿瘤进展和肿瘤增殖性干细胞样肿瘤细胞。
核心结论
- 数据支持在精准医学方法中对ERG阳性前列腺癌进行EC-8042的临床测试。
- 数据表明有必要在临床试验中进一步评估EC-8042。
研究设计与样本
- 在细胞培养和ERG/PTEN转基因/敲除小鼠中评估EC-8042活性。
- 使用新方案从ERG/PTEN小鼠生成肿瘤球,检查EC-8042对具有高自我更新和致瘤能力的肿瘤增殖性干细胞样癌细胞的影响。
主要发现
- EC-8042阻断ERG调控基因转录并逆转VCaP细胞的侵袭和转移表型。
- EC-8042阻断VCaP细胞和小鼠来源肿瘤球中干细胞样肿瘤细胞的扩增。
- 在ERG/PTEN小鼠中,EC-8042全身治疗抑制ERG调控基因转录、肿瘤进展和肿瘤增殖性干细胞样肿瘤细胞。
临床怎么用
- 作者认为数据支持在精准医学方法中对ERG阳性前列腺癌进行EC-8042的临床测试。
- 作者认为有必要在临床试验中进一步评估EC-8042。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The TMPRSS2-ERG gene fusion is the most frequent genetic rearrangement in prostate cancers and results in broad transcriptional reprogramming and major phenotypic changes. Interaction and cooperation of ERG and SP1 may be instrumental in sustaining the tumorigenic and metastatic phenotype and could represent a potential vulnerability in ERG fusion-positive tumors. OBJECTIVE: To test the activity of EC-8042, a compound able to block SP1, in cellular and mouse models of ERG-positive prostate cancer. DESIGN, SETTING, AND PARTICIPANTS: We evaluated the activity of EC-8042 in cell cultures and ERG/PTEN transgenic/knockout mice that provide reliable models for testing novel therapeutics in this specific disease context. Using a new protocol to generate tumor spheroids from ERG/PTEN mice, we also examined the effects of EC-8042 on tumor-propagating stem-like cancer cells with high self-renewal and tumorigenic capabilities. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The efficacy of EC-8042 was determined by measuring the proliferative capacity and target gene expression in cell cultures, invasive and metastatic capabilities in chick chorioallantoic membrane assays, and tumor development in mice. Significance was determined using statistical test. RESULTS AND LIMITATIONS: EC-8042 blocked transcription of ERG-regulated genes and reverted the invasive and metastatic phenotype of VCaP cells. EC-8042 blocked the expansion of stem-like tumor cells in tumor spheroids from VCaP cells and mouse-derived tumors. In ERG/PTEN mice, systemic treatment with EC-8042 inhibited ERG-regulated gene transcription, tumor progression, and tumor-propagating stem-like tumor cells. CONCLUSIONS: Our data support clinical testing of EC-8042 for the treatment of ERG-positive prostate cancer in precision medicine approaches. PATIENT SUMMARY: In this study, EC-8042, a novel compound with a favorable pharmacological and toxicological profile, exhibited relevant activity in cell cultures and in vivo in a genetically engineered mouse model that closely recapitulates the features of clinically aggressive ERG-positive prostate cancer. Our data indicate that further evaluation of EC-8042 in clinical trials is warranted.
引用
- Shinde D, Albino D, Zoma M, et al. Transcriptional Reprogramming and Inhibition of Tumor-propagating Stem-like Cells by EC-8042 in ERG-positive Prostate Cancer. Eur Urol Oncol. 2018. PMID: 31277777. doi:10.1016/j.euo.2018.08.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。